Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer
Disappointment For AstraZeneca
Executive Summary
Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.